Neomorph

Neomorph is a private, pre-clinical stage biotech pioneering the field of targeted protein degradation (TPD) to address historically intractable disease targets. The company differentiates itself through a deep focus on molecular glue degraders, a promising class of TPD therapeutics that can degrade proteins without requiring a traditional druggable binding pocket. Backed by leading experts and venture capital, Neomorph is building a platform and pipeline aimed at curing diseases by destroying pathogenic proteins. Its success hinges on translating complex TPD science into clinically viable drugs.

Platform for the discovery and development of targeted protein degraders, with a specialized focus on molecular glue degraders that induce novel interactions between E3 ubiquitin ligases and disease-causing proteins to mark them for proteasomal destruction.

Neomorph operates in the highly competitive targeted protein degradation space, competing with public companies like Kymera Therapeutics, Nurix Therapeutics, and Arvinas, as well as numerous private biotechs and large pharma internal efforts. Its differentiated focus on molecular glues sets it apart from many peers initially built on PROTAC technology.